Your SlideShare is downloading. ×
0
3 Reasons the Market Is
Down on Gilead Sciences
2013’s Market Darling...
...Hasn’t Seen the Love Continue
1. Remember That First Chart?
• The stock has doubled over the last year, but if we
zoom out a little more it’s been quite...
2. Sovaldi, Sovaldi, Sovaldi
• Hepatitis C drug approved in Dec.
• Multi-billion dollar potential.
• Combination product u...
About Pricing and...
Competition
• AbbVie’s (NYSE: ABBV) combination product is just
a few months behind Gilead’s (Nasdaq: GILD)
Sovaldi combin...
3. The Whole Industry Is Down
• Gilead has underperformed the index for the year...
3. The Whole Industry Is Down
• But if you look since the peak, it’s matching the
index.
• Investors are
shying away from
...
Where’s the Bottom?
• Hard to predict.
• Pricing issues might blow over, but worry about
competition will continue until G...
Think Long Term
• If you’re planning on holding for multiple years,
catching the bottom doesn’t matter too much.
• Gilead ...
6 Stock Picks Poised for
Incredible Growth
Upcoming SlideShare
Loading in...5
×

3 Reasons the Market Is Down on Gilead Sciences

8,562

Published on

After a solid two-year run, Gilead Sciences (NASDAQ: GILD) has fallen from investors graces, down for the year. The biotech has become increasingly reliant on its hepatitis C drug Sovaldi with competition from AbbVie (NYSE: ABBV) and Merck (NYSE: MRK) around the corner

0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
8,562
On Slideshare
0
From Embeds
0
Number of Embeds
15
Actions
Shares
0
Downloads
5
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide

Transcript of "3 Reasons the Market Is Down on Gilead Sciences"

  1. 1. 3 Reasons the Market Is Down on Gilead Sciences
  2. 2. 2013’s Market Darling...
  3. 3. ...Hasn’t Seen the Love Continue
  4. 4. 1. Remember That First Chart? • The stock has doubled over the last year, but if we zoom out a little more it’s been quite a run. • Some investors are likely selling to lock-in gains.
  5. 5. 2. Sovaldi, Sovaldi, Sovaldi • Hepatitis C drug approved in Dec. • Multi-billion dollar potential. • Combination product under FDA review will increase use. • With 2013 revenue of $11.2 billion, Sovaldi sales will have a substantial impact on Gilead’s earnings. • With reliance, comes worry... Source: Gilead Sciences
  6. 6. About Pricing and...
  7. 7. Competition • AbbVie’s (NYSE: ABBV) combination product is just a few months behind Gilead’s (Nasdaq: GILD) Sovaldi combination, but it doesn’t appear to be as convenient to take. • Merck (NYSE: MRK) is further behind, but looks like it has a combination pill that works as well as Gilead’s combo – cure rates in the 95%+ range – and could be taken just once per day. Phase 3 data should be available next year.
  8. 8. 3. The Whole Industry Is Down • Gilead has underperformed the index for the year...
  9. 9. 3. The Whole Industry Is Down • But if you look since the peak, it’s matching the index. • Investors are shying away from the biotech’s risk.
  10. 10. Where’s the Bottom? • Hard to predict. • Pricing issues might blow over, but worry about competition will continue until Gilead proves its dominance. • End of industry downturn will be determined by investors’ risk tolerance, which could tighten further.
  11. 11. Think Long Term • If you’re planning on holding for multiple years, catching the bottom doesn’t matter too much. • Gilead is expected to generate its market cap in cash over the next seven years. • Even if it takes 10 years, it’s a substantial deal for a company with growth potential.
  12. 12. 6 Stock Picks Poised for Incredible Growth
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×